The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring

Clinical Transplantation

Volumn 16, Issue 4, 2002, Pages 262-272

  Felipe, Claudia R ^a   Silva Jr , Helio T ^a   Machado, Paula G P ^a   Garcia, Riberto ^a   Da Silva Moreira, Silvia R ^a   Pestana, José O M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Kidney transplant; Pharmacokinetic; Race; Tacrolimus

Indexed keywords

AZATHIOPRINE; METHYLPREDNISOLONE; OKT 3; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; FEMALE; GENETIC VARIABILITY; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECIPIENT; BLOOD; MIDDLE AGED; MULTICENTER STUDY; RACE; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGE; RACIAL STOCKS; TACROLIMUS; TIME FACTORS; CONTINENTAL POPULATION GROUPS; HUMANS; MIDDLE AGED;

EID: 0036021962     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2002.01103.x     Document Type: Article

References (36)

1. Current opinions on therapeutic drug monitoring of immunosuppressive drugs
2. Advancing the art of immunnosuppression with the science of pharmacology
3. Effect of race on renal transplant outcome
4. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects
5. Cyclosporine bio-availability of Neoral and Sandimmune in white and black de novo renal transplant recipients
6. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
7. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine
8. Racial variation in dosage requirements of tacrolimus
9. Inummosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients
10. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients
11. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
12. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group
13. Effect of race and immunosuppression in renal transplantation: Three-year survival results from a US multicenter, randomized trial
14. Phase III study of FK 506 in kidney transplantation
15. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics
16. Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients
17. Cytochrorne P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans
18. Analytical validation of the PRO-Trac II ELISA for the determination of tacrolimus (FK506) in whole blood
19. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation
20. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants
21. High variability of drug exposure: A biopharmaceutic risk factor for chronic rejection
22. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients - Importance of trough level as a practical indicator
23. Clinical pharmacokinetics of tacrolimus in heart transplant recipients
24. An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants
25. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation
26. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients
27. Phase II FK 506 multicenter concentration control study: One-year follow-up
28. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients
29. Low systemic exposure to tacrolimus correlates with acute rejection
30. Dosing and management guidelines for tacrolimus in renal transplant patients
31. Molecular and physical mechanisms of first-pass extraction
32. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient
33. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection
34. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
35. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
36. Pharmacological surrogates of allograft outcome